The FDA approved a combination of trifluridine, tipiracil, and bevacizumab for the treatment of heavily pretreated metastatic colorectal cancer. The U.S. Food and Drug Administration (FDA) has approved trifluridine and tipiracil (Lonsurf), in combination...
The FDA has approved an immune checkpoint inhibitor in combination with chemotherapy to treat certain adult patients with endometrial cancer The U.S. Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli) in combination with...
Less than four minutes of physical activity per day linked to lower cancer risk, and vaccination helped improve outcomes for cancer patients with COVID-19.
Improved patient outcomes come from new treatments. New treatments stem from successful clinical trials. Clinical trials build on discoveries made in the lab. And laboratory discoveries? Those rely on a vast array of assays...
ASCO guideline emphasizes the importance of assessment for older cancer patients, and a change in mammogram recommendations reignites screening debates.
The FDA has approved an inhibitor of FLT3 for use across multiple phases of acute myeloid leukemia treatment. The U.S. Food and Drug Administration (FDA) has approved quizartinib (Vanflyta) for the treatment of patients...
Black Men With Melanoma Have Higher Risk of Dying, and CAR T-cell Therapy Provides Hope for Aggressive Lymphoma.
Researchers find increased risk of four types of secondary cancer in patients diagnosed with early-onset colorectal cancer.
Reducing cancer treatment to improve quality of life without lowering effectiveness, and death rates are climbing for certain cancers in Hispanic Americans.
Antibody-drug conjugates link a targeted medication with a toxic drug to deliver a potent payload inside cancer cells.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More